drugset / Trial / NCT01297517

Efficacy and Safety Study of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% and Brimonidine 0.2%

NCT01297517

Phase 3 Completed 1001 enrolled Alcon Research
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study was to evaluate the efficacy and safety of a fixed combination of Brinzolamide/Brimonidine in lowering intraocular pressure (IOP) relative to each of its individual active components in patients with open-angle glaucoma and/or ocular hypertension.

Timeline

Start
2011-02
Primary completion
2012-03
Completion
2012-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Brimonidine Small molecule 0.2 % Topical
Comparator Brinzolamide Small molecule 1 % Topical
Subject Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension Unknown Topical